BSE Live
Mar 12, 16:01Prev. Close
216.15
Open Price
212.10
Bid Price (Qty.)
208.00 (25)
Offer Price (Qty.)
209.35 (100)
NSE Live
Mar 12, 15:59Prev. Close
216.26
Open Price
214.57
Bid Price (Qty.)
209.20 (619)
Offer Price (Qty.)
0.00 (0)
| Key Financial Ratios of Bliss GVS Pharma (in Rs. Cr.) | Mar 15 | Mar 14 | Mar 13 | Mar 12 | Mar 11 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | 5.82 | 5.23 | 5.50 | 5.12 | 3.94 | |
| Diluted EPS (Rs.) | 5.82 | 5.23 | 5.50 | 5.12 | 3.94 | |
| Cash EPS (Rs.) | 6.31 | 5.66 | 5.92 | 5.48 | 4.47 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 35.70 | 30.52 | 25.08 | 20.40 | 16.15 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 35.70 | 30.52 | 25.08 | 20.40 | 16.15 | |
| Dividend / Share(Rs.) | 0.70 | 0.50 | 0.70 | 0.75 | 0.60 | |
| Revenue from Operations/Share (Rs.) | 30.35 | 28.16 | 34.29 | 25.85 | 21.22 | |
| PBDIT/Share (Rs.) | 10.43 | 9.33 | 11.23 | 8.47 | 5.87 | |
| PBIT/Share (Rs.) | 9.93 | 8.89 | 10.80 | 8.12 | 5.34 | |
| PBT/Share (Rs.) | 8.85 | 7.98 | 10.16 | 7.73 | 5.14 | |
| Net Profit/Share (Rs.) | 5.82 | 5.23 | 5.50 | 5.12 | 3.94 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | 34.35 | 33.11 | 32.74 | 32.76 | 27.69 | |
| PBIT Margin (%) | 32.73 | 31.58 | 31.49 | 31.40 | 25.19 | |
| PBT Margin (%) | 29.15 | 28.33 | 29.64 | 29.89 | 24.21 | |
| Net Profit Margin (%) | 19.17 | 18.56 | 16.02 | 19.81 | 18.56 | |
| Return on Networth / Equity (%) | 16.30 | 17.12 | 21.90 | 25.10 | 24.38 | |
| Return on Capital Employed (%) | 14.74 | 14.69 | 17.85 | 24.56 | 23.78 | |
| Return on Assets (%) | 10.81 | 11.08 | 12.42 | 19.54 | 19.03 | |
| Total Debt/Equity (X) | 0.16 | 0.22 | 0.28 | 0.02 | 0.04 | |
| Asset Turnover Ratio (%) | 56.40 | 59.71 | 77.52 | 98.64 | 102.50 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 2.38 | 2.52 | 2.10 | 3.83 | 3.67 | |
| Quick Ratio (X) | 2.23 | 2.34 | 1.92 | 3.60 | 3.40 | |
| Inventory Turnover Ratio (X) | 13.90 | 13.68 | 14.39 | 21.03 | 18.85 | |
| Dividend Payout Ratio (NP) (%) | 12.03 | 9.56 | 12.73 | 14.64 | 15.23 | |
| Dividend Payout Ratio (CP) (%) | 11.09 | 8.83 | 11.81 | 13.69 | 13.42 | |
| Earnings Retention Ratio (%) | 87.97 | 90.44 | 87.27 | 85.36 | 84.77 | |
| Cash Earnings Retention Ratio (%) | 88.91 | 91.17 | 88.19 | 86.31 | 86.58 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 1,341.81 | 453.16 | 316.47 | 186.56 | 222.07 | |
| EV/Net Operating Revenue (X) | 4.29 | 1.56 | 0.89 | 0.70 | 1.01 | |
| EV/EBITDA (X) | 12.48 | 4.71 | 2.73 | 2.13 | 3.66 | |
| MarketCap/Net Operating Revenue (X) | 4.25 | 1.58 | 0.78 | 0.90 | 1.07 | |
| Retention Ratios (%) | 87.96 | 90.43 | 87.26 | 85.35 | 84.76 | |
| Price/BV (X) | 3.61 | 1.46 | 1.06 | 1.14 | 1.40 | |
| Price/Net Operating Revenue | 4.25 | 1.58 | 0.78 | 0.90 | 1.07 | |
| Earnings Yield | 0.05 | 0.12 | 0.21 | 0.22 | 0.17 |
13.03.2026
11.03.2026
10.03.2026
09.03.2026
20.02.2026
Bliss GVS Consolidated December 2025 Net Sales at Rs 218.25 crore, up 3.72% Y-o-Y
19.02.2026
Bliss GVS Standalone December 2025 Net Sales at Rs 164.68 crore, down 8.3% Y-o-Y
07.11.2025
Bliss GVS Consolidated September 2025 Net Sales at Rs 244.40 crore, up 12.27% Y-o-Y
30.07.2025
Bliss GVS Consolidated June 2025 Net Sales at Rs 207.47 crore, up 12.97% Y-o-Y
20.02.2026
Bliss GVS Consolidated December 2025 Net Sales at Rs 218.25 crore, up 3.72% Y-o-Y
19.02.2026
Bliss GVS Standalone December 2025 Net Sales at Rs 164.68 crore, down 8.3% Y-o-Y
07.11.2025
Bliss GVS Consolidated September 2025 Net Sales at Rs 244.40 crore, up 12.27% Y-o-Y
30.07.2025
Bliss GVS Consolidated June 2025 Net Sales at Rs 207.47 crore, up 12.97% Y-o-Y
13.03.2026
13.03.2026
11.03.2026
Granules India looks for M&A as it expands beyond the US, deepens focus on complex generics
11.03.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
22.01.2026
Dr Reddy’s stock jumps over 4% today as brokerages turn bullish after Q3 results beat estimates
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
22.01.2026
Dr Reddy’s stock jumps over 4% today as brokerages turn bullish after Q3 results beat estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities